Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ciclopirox. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | ALOX12 | P18054 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.81 |
| ▸ | KDM4B | O94953 | 1/20 | 0.81 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.81 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.81 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.81 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.81 |
| ▸ | IDH1 | O75874 | 11/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ciclopirox SCHEMBL1411724 | 1.00 | KDM4E (1.00) | KDM4ELMNATP53CYP1A2ALOX12 | |
| Ciclopirox SCHEMBL66960 | 1.00 | KDM4E (1.00) | KDM4ELMNATP53CYP1A2ALOX12 | |
| Ciclopirox SCHEMBL6264129 | 0.95 | KDM4E (0.90) | KDM4ELMNATP53CYP1A2ALOX12 | |
| Ciclopirox SCHEMBL28169345 | 0.95 | KDM4E (0.90) | KDM4ELMNATP53CYP1A2ALOX12 | |
| Ciclopirox SCHEMBL30969895 | 0.90 | NR1I2 (0.94) | KDM4ELMNATP53CYP1A2ALOX12 | |
| Ciclopirox SCHEMBL34424 | 0.90 | NR1I2 (1.00) | KDM4ELMNATP53CYP1A2ALOX12 | |
| Ciclopirox SCHEMBL1818483 | 0.90 | NR1I2 (1.00) | KDM4ELMNATP53CYP1A2ALOX12 | |
| Ciclopirox SCHEMBL4886428 | 0.85 | KDM4E (0.72) | KDM4ELMNATP53CYP1A2ALOX12 | |
| Ciclopirox SCHEMBL21571455 | 0.84 | NR1I2 (0.83) | KDM4ELMNATP53CYP1A2ALOX12 | |
| Ciclopirox SCHEMBL27927647 | 0.83 | KDM4E (0.71) | KDM4ELMNATP53CYP1A2ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9114117-B2 | Compounds effective against cancer | INGO SCHMIDT-WOLF (DE) | 2015-08-25 | — | — | US | disclosed |
| US-20120028993-A1 | Compounds Effective Against Cancer | SCHMIDT-WOLF INGO (DE) | 2012-02-02 | — | — | US | disclosed |
| EP-2379068-A1 | COMPOUNDS EFFECTIVE AGAINST CANCER | Schmidt-Wolf, Ingo (DE) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010081486-A1 | COMPOUNDS EFFECTIVE AGAINST CANCER | SCHMIDT-WOLF INGO (DE) | 2010-07-22 | — | — | WO | disclosed |
| US-6087400-A | MIXTURE CONTAINING BENZALKONIUM CHLORIDE AND WATER | WOODWARD LABORATORIES, INC. (US) | 2000-07-11 | — | — | US | disclosed |
| US-5994383-A | MIXTURE CONTAINING BENZALKONIUM CHLORIDE AND WATER | WOODWARD LABORATORIES, INC. (US) | 1999-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028993-A1 | Compounds Effective Against Cancer | ALOX5, ACOX3, ACOX1 | KDM4E 2624/4885LMNA 3504/4885TP53 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.